

Editorial



The Intertwined Relationship Between Heart Failure and Atrial Fibrillation, How Can We Untangle It?

Ran Heo , MD, PhD

Division of Cardiology, Department of Internal Medicine, Hanyang University Medical Center, College of Medicine, Hanyang University, Seoul, Korea



► See the article “Lower Atrial Fibrillation Risk With Sodium-Glucose Cotransporter 2 Inhibitors Than With Dipeptidyl Peptidase-4 Inhibitors in Individuals With Type 2 Diabetes: A Nationwide Cohort Study” in volume 54 on page 256.

Received: Apr 10, 2024

Accepted: May 7, 2024

Published online: May 9, 2024

Correspondence to

Ran Heo, MD, PhD

Division of Cardiology, Department of Internal Medicine, Hanyang University Medical Center, College of Medicine, Hanyang University, 222-1, Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea.

Email: cardiohr@hanyang.ac.kr

Copyright © 2024. The Korean Society of Cardiology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Ran Heo 

<https://orcid.org/0000-0002-2675-3612>

Funding

The author received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest

The author has no financial conflicts of interest.

Atrial fibrillation (AF) and heart failure (HF) are medical burdens and increasing in prevalence. Both are associated with multiple comorbidities and adverse outcomes.^{1,2)} They share risk factors that contribute to adverse remodeling. One can exacerbate the other and their combination leads to increased patient morbidity and mortality.³⁾

Diabetes is a shared risk factor for both diseases. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase-4 inhibitors (DPP4i) are newer recommended options for diabetic treatment. Considering the cardiovascular complications in diabetic patients, the cardiovascular benefits of these agents are of medical interest, including the potential reduction of AF risk.

However, studies examining AF risk reduction with SGLT2i have yielded inconsistent results across different methodologies and study populations. In one study, based on the observational and cohort data, SGLT2i was not associated with AF reduction compared with other glucose-lowering drugs, despite its beneficial impact on other cardiovascular outcomes.⁴⁾ Meta-analyses comparing SGLT2i and placebo in randomized controlled studies also yielded inconsistent results regarding new AF occurrence. Notably, the ethnicity of participants in SGLT2i trials was predominantly white approximately 70% to 80%.^{5,6)}

In this issue, Kim et al.⁷⁾ reported the beneficial impact of SGLT2i in lowering new-onset AF risk using a total of 42,786 propensity-matched pairs from the Korean nationwide cohort data. This result is concordant with several other studies comparing the risk of new-onset AF between SGLT2i and DPP4i. Studies using the data from Taiwan⁸⁾ and Hong Kong⁹⁾ also demonstrated a 39% and 32% reduction of new-onset AF in the SGLT2i group, respectively. On the contrary, studies conducted in Scandinavian countries with 28,408 and 40,908 patients showed no significant AF risk reduction between SGLT2i and other diabetic treatments.^{10,11)} These contrasting results need to be resolved in future studies.

Randomized trials offer high-level evidence. However, assessing AF risk based on previous trials is challenging, as SGLT2i trials were not primarily designed to evaluate AF risk. Furthermore, the study settings were heterogeneous, including diverse AF assessment protocols. Imbalance in ethnicity should be highlighted when interpreting the results of trials.

Data Sharing Statement

The data generated in this study is available from the corresponding author upon reasonable request.

The contents of the report are the author's own views and do not necessarily reflect the views of the *Korean Circulation Journal*.

Therefore, the current article holds strength in its aim to demonstrate AF risk reduction between two recent, widely used diabetic agents. The implications of this research could prove valuable for managing AF risk in diabetic patients. Further studies investigating AF risk between SGLT2i and other diabetic treatments are warranted with the consideration of ethnic differences.

REFERENCES

1. Park SM, Lee SY, Jung MH, et al. Korean Society of Heart Failure guidelines for the management of heart failure: management of the underlying etiologies and comorbidities of heart failure. *Korean Circ J* 2023;53:425-51. [PUBMED](#) | [CROSSREF](#)
2. Youn JC, Kim D, Cho JY, et al. Korean Society of Heart Failure guidelines for the management of heart failure: treatment. *Korean Circ J* 2023;53:217-38. [PUBMED](#) | [CROSSREF](#)
3. Batul SA, Gopinathannair R. Atrial fibrillation in heart failure: a therapeutic challenge of our times. *Korean Circ J* 2017;47:644-62. [PUBMED](#) | [CROSSREF](#)
4. Li CX, Liang S, Gao L, Liu H. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis. *PLoS One* 2021;16:e0244689. [PUBMED](#) | [CROSSREF](#)
5. Usman MS, Siddiqi TJ, Memon MM, et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. *Eur J Prev Cardiol* 2018;25:495-502. [PUBMED](#) | [CROSSREF](#)
6. Fernandes GC, Fernandes A, Cardoso R, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. *Heart Rhythm* 2021;18:1098-105. [PUBMED](#) | [CROSSREF](#)
7. Kim M, Ha KH, Lee J, et al. Lower atrial fibrillation risk with sodium-glucose cotransporter 2 inhibitors than with dipeptidyl peptidase-4 inhibitors in individuals with type 2 diabetes: a nationwide cohort study. *Korean Circ J* 2024;54:256-67. [PUBMED](#) | [CROSSREF](#)
8. Ling AW, Chan CC, Chen SW, et al. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. *Cardiovasc Diabetol* 2020;19:188. [PUBMED](#) | [CROSSREF](#)
9. Lee S, Zhou J, Leung KS, et al. Comparison of sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in diabetic patients: a propensity score-matched study in Hong Kong. *Cardiovasc Drugs Ther* 2023;37:561-9. [PUBMED](#) | [CROSSREF](#)
10. Norhammar A, Bodegård J, Nyström T, Thuresson M, Nathanson D, Eriksson JW. Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: a nationwide observational study. *Diabetes Obes Metab* 2019;21:1136-45. [PUBMED](#) | [CROSSREF](#)
11. Persson F, Nyström T, Jørgensen ME, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. *Diabetes Obes Metab* 2018;20:344-51. [PUBMED](#) | [CROSSREF](#)